Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China

BACKGROUND: Sunitinib was approved several years ago as a first-line drug for treating metastatic renal cell carcinoma (mRCC); however, its high price and broad side effects when administered at the standard dose have limited its clinical use. A clinical trial (NCT02072031) confirmed that anlotinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jingyang, Fang, Qingxia, Zheng, Xiaochun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904460/
https://www.ncbi.nlm.nih.gov/pubmed/36749752
http://dx.doi.org/10.1371/journal.pone.0281402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904460/
https://www.ncbi.nlm.nih.gov/pubmed/36749752
http://dx.doi.org/10.1371/journal.pone.0281402

Ejemplares similares